Home/Filings/4/0001264124-12-000194
4//SEC Filing

Mihalik Vincent P 4

Accession 0001264124-12-000194

CIK 0000881464other

Filed

Aug 9, 8:00 PM ET

Accepted

Aug 10, 6:38 PM ET

Size

32.3 KB

Accession

0001264124-12-000194

Insider Transaction Report

Form 4
Period: 2012-08-08
Mihalik Vincent P
SVP Sales and Marketing, CCO
Transactions
  • Other

    Common Stock

    2012-08-08$31.00/sh452.9$14,0400 total(indirect: By 401(k))
  • Other

    Common Stock

    2012-08-08$31.00/sh1,799.4$55,7812,720 total(indirect: by ESOP)
  • Other

    Incentive Stock Option (right to buy)

    2012-08-08$31.00/sh7,021$217,6510 total
    Exercise: $16.02Exp: 2019-03-06Common Stock (7,021 underlying)
  • Other

    Non-Qualified Stock Option (right to buy)

    2012-08-08$31.00/sh34,514$1,069,9340 total
    Exercise: $13.05Exp: 2016-02-10Common Stock (34,514 underlying)
  • Other

    Non-Qualified Stock Option (right to buy)

    2012-08-08$31.00/sh42,979$1,332,3490 total
    Exercise: $16.02Exp: 2019-03-06Common Stock (42,979 underlying)
  • Other

    Common Stock

    2012-08-08$31.00/sh1,360$42,1600 total(indirect: by ESOP)
  • Other

    Incentive Stock Option (right to buy)

    2012-08-08$31.00/sh25,486$790,0660 total
    Exercise: $13.05Exp: 2016-02-10Common Stock (25,486 underlying)
  • Other

    Common Stock

    2012-08-08$31.00/sh1,360$42,1601,360 total(indirect: by ESOP)
  • Other

    Non-Qualified Stock Option (right to buy)

    2012-08-08$31.00/sh33,593$1,041,3830 total
    Exercise: $15.03Exp: 2018-03-01Common Stock (33,593 underlying)
  • Other

    Performance Shares

    2012-08-0885,0000 total
    Common Stock (85,000 underlying)
  • Other

    Common Stock

    2012-08-08$31.00/sh885.3$27,444452.9 total(indirect: By 401(k))
  • Other

    Common Stock

    2012-08-08$31.00/sh39,917$1,237,4270 total
  • Other

    Incentive Stock Option (right to buy)

    2012-08-08$31.00/sh6,407$198,6170 total
    Exercise: $15.03Exp: 2018-03-01Common Stock (6,407 underlying)
  • Other

    Incentive Stock Option (right to buy)

    2012-08-08$31.00/sh6,032$186,9920 total
    Exercise: $18.01Exp: 2017-02-02Common Stock (6,032 underlying)
  • Other

    Non-Qualified Stock Option (right to buy)

    2012-08-08$31.00/sh48,968$1,518,0080 total
    Exercise: $18.01Exp: 2017-02-02Common Stock (48,968 underlying)
Footnotes (4)
  • [F1]Represents a sale of shares to B&R Acquisition Company, a wholly-owned subsidiary of Bristol-Myers Squibb Company, either through directly tendering such shares or by virtue of a sale in the merger pursuant to the Agreement and Plan of Merger, dated as of June 29, 2012, among Bristol-Myers Squibb Company, B&R Acquisition Company and Amylin Pharmaceuticals, Inc. Includes unvested restricted stock units that were cancelled at the effective time of the merger in exchange for the right to receive cash payment for such restricted stock units at a price of $31.00 per restricted stock unit.
  • [F2]Represents a sale of shares to B&R Acquisition Company, a wholly-owned subsidiary of Bristol-Myers Squibb Company, either through directly tendering such shares or by virtue of a sale in the merger pursuant to the Agreement and Plan of Merger, dated as of June 29, 2012, among Bristol-Myers Squibb Company, B&R Acquisition Company and Amylin Pharmaceuticals, Inc.
  • [F3]Pursuant to the Agreement and Plan of Merger, dated as of June 29, 2012, among Bristol-Myers Squibb Company, B&R Acquisition Company and Amylin Pharmaceuticals, Inc., these options, whether or not vested, were cancelled at the effective time of the merger in exchange for the right to receive cash payment in the amount of $31.00 per option less the exercise price of such option.
  • [F4]Pursuant to the Agreement and Plan of Merger, dated as of June 29, 2012, among Bristol-Myers Squibb Company, B&R Acquisition Company and Amylin Pharmaceuticals, Inc., these performance-based restricted stock units, whether or not vested, were canceled prior to consummation of the merger in exchange for the right to receive cash payment for each such restricted stock unit at a price of $31.00 per restricted stock unit.

Issuer

AMYLIN PHARMACEUTICALS INC

CIK 0000881464

Entity typeother

Related Parties

1
  • filerCIK 0001455318

Filing Metadata

Form type
4
Filed
Aug 9, 8:00 PM ET
Accepted
Aug 10, 6:38 PM ET
Size
32.3 KB